Biological Safety Testing Market

1. Biologics are products manufactured or extracted from biological sources such as living organisms, and may involve the use of recombinant DNA technology. Over the past five decades, uniform protocols have been developed for safety and toxicity testing of small molecules. On the other hand, biologics have a unique set of properties not usually present in small molecules. As such, the safety testing of biologics is more difficult and requires specialized evaluation. Know More | Download PDF Brochure: - http://tinyurl.com/oexjbv6 The major drivers for the market are the increase in pharmaceutical and biotechnology firms and the increase in government and private funding for life science research. The rise in population, rise in disease burden, and the trend of automation in biologic safety testing will also aid the growth of this market. On the other hand, stringent regulatory policies will restrain the growth of this market. The current FDA approval process for medical devices is lengthy and complex, and poses a major challenge to companies launching new and innovative products. The report “Biological Safety Testing Market by Application (Stem Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), & Test (Bioburden, Endotoxin, Cell Line Authentication, Residual Contamination, Adventitious Agents) - Global Forecast to 2019”, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global biologics safety testing market along with the estimates and forecasts of the revenue and market share analysis. Speak to Analyst/Expert: - http://tinyurl.com/nozjkhc

2. Browse 76 market data tables and 108 figures spread through 165 pages and in-depth TOC on “Biological Safety Testing Market by Application (Stem Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), & Test (Bioburden, Endotoxin, Cell Line Authentication, Residual Contamination, Adventitious Agents) - Global Forecast to 2019" http://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market- 34624144.html Early buyers will receive 10% customization on reports. The rapidly increasing pharmaceutical and biotechnology industries and increasing number of new biologics products launched will be the two most important growth drivers for this market in the forecast period (2014-2019). For instance, the number of new products launched annually witnessed a strong upward trend between 2003 and 2013. The number of new products launched in 2013 was 56, as compared to 29 in 2003. The biologics pipeline has increased by 155%, from 355 treatments in 2001 to 907 in 2012. A strong pharmaceutical product pipeline will aid the growth of the pharmaceutical and biotechnology industry, which is an important end user of biologics safety testing products. Moreover, increasing government support for the pharmaceutical and biotechnology industries will further boost the demand for biologics safety testing products. In 2013, the European Research Council awarded $830 million for life sciences research projects across Europe. A similar trend can be observed in Asia. For instance, beginning from 2014, the Indian government plans to invest up to $5 billion a year for the next five years to boost the biotechnology sector in the country and make it a $100- billion industry by 2025. This increases the purchasing power of major

3. research institutes, which in turn is driving the market for biologics safety testing products. Major players in the biologics safety testing market include Charles River Laboratories International, Inc. (U.S.), Lonza Group (Switzerland), Sigma- Aldrich Corporation (U.S.), SGS SA (Switzerland), WuXi PharmaTech (Cayman), Inc. (China), Avance Biosciences, Inc. (U.S.), BSL Bioservice (Germany), Cytovance Biologics, Inc. (U.S.), Merck & Co., Inc. (U.S.), and Toxikon Corporation (U.S.).